Last reviewed · How we verify
vaccination with 2 doses of Shingrix vaccine
vaccination with 2 doses of Shingrix vaccine is a Small molecule drug developed by Region Skane. It is currently FDA-approved.
At a glance
| Generic name | vaccination with 2 doses of Shingrix vaccine |
|---|---|
| Sponsor | Region Skane |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster (PHASE3)
- Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV (PHASE4)
- A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response (PHASE3)
- Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients (NA)
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases (PHASE4)
- Simultaneous RZV and aIIV4 Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vaccination with 2 doses of Shingrix vaccine CI brief — competitive landscape report
- vaccination with 2 doses of Shingrix vaccine updates RSS · CI watch RSS
- Region Skane portfolio CI
Frequently asked questions about vaccination with 2 doses of Shingrix vaccine
What is vaccination with 2 doses of Shingrix vaccine?
vaccination with 2 doses of Shingrix vaccine is a Small molecule drug developed by Region Skane.
Who makes vaccination with 2 doses of Shingrix vaccine?
vaccination with 2 doses of Shingrix vaccine is developed and marketed by Region Skane (see full Region Skane pipeline at /company/region-skane).
What development phase is vaccination with 2 doses of Shingrix vaccine in?
vaccination with 2 doses of Shingrix vaccine is FDA-approved (marketed).